NIKKEI 225
38,527.60 -309.86 (-0.80%) HANG SENG
18,511.24 +67.13 (+0.36%) CRUDE OIL
73.19 -0.06 (-0.08%) GOLD FUTURES
2,355.10 +7.70 (+0.33%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,442.52 +1,260.61 (+2.33%)
MRK Jan 2026 185.000 call
| Previous close | 1.6200 |
| Open | 1.6200 |
| Bid | 1.1900 |
| Ask | 2.1300 |
| Strike | 185.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.6200 - 1.6200 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
BenzingaModerna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
Simply Wall St.Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
BenzingaSummit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
